(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 199.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Bioxcel Therapeutics's revenue in 2024 is $1,380,000.On average, 2 Wall Street analysts forecast BTAI's revenue for 2024 to be $114,509,633, with the lowest BTAI revenue forecast at $76,135,911, and the highest BTAI revenue forecast at $152,883,355. On average, 2 Wall Street analysts forecast BTAI's revenue for 2025 to be $330,228,047, with the lowest BTAI revenue forecast at $305,766,710, and the highest BTAI revenue forecast at $354,689,384.
In 2026, BTAI is forecast to generate $1,375,950,195 in revenue, with the lowest revenue forecast at $1,375,950,195 and the highest revenue forecast at $1,375,950,195.